ERBB2 and gastric cancer: Trastuzumab for Gastric Cancer (ToGA) study showed that trastuzumab plus chemotherapy improved overall survival compared with chemotherapy alone in treating metastatic, unresectable HER2 positive (HER2(+)) GC [5].